Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug vedotin, the first new ADC to read out pivotal data following its $43 billion acquisition of Seagen, has stumbled in a phase 3 study in…
Pfizer's new antibody-drug conjugate (ADC), sigvotatug vedotin, failed its Phase 3 trial for non-small cell lung cancer. This marks a setback for the first pivotal data readout since the $43 billion acquisition of Seagen. The failure represents a significant "speed bump" for…
Market Samachar is a news aggregator. This article was originally published by FierceBiotech. Tap the button above to read the full story on their site.